PRC2 targeting is a therapeutic strategy for EZ score defined high-risk multiple myeloma patients and overcome resistance to IMiDs
Laurie Herviou(Centre National de la Recherche Scientifique), Jérôme Moreaux(Centre National de la Recherche Scientifique)
Cited by 47
Related Papers
Antioxidant Defenses Confer Resistance to High Dose Melphalan in Multiple Myeloma Cells
|Cancers|2019|30
Identification of a 20-Gene Expression-Based Risk Score as a Predictor of Clinical Outcome in Chronic Lymphocytic Leukemia Patients
|BioMed Research International|2014|20
Transient loss of Polycomb components induces an epigenetic cancer fate
|bioRxiv (Cold Spring Harbor Laboratory)|2023|12